Abrocitinib
Sign in to save this workspacePrimary targets: JAK1 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.50
Gini
0.581
CATDS
0.024
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Abrocitinib. Strongest target: JAK1 at 98.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK1 | 98.7% | 1.3% |
| 2 | JAK2 | 92.6% | 7.4% |
| 3 | TYK2 | 89.9% | 10.1% |
| 4 | LRRK2 | 62.1% | 37.9% |
| 5 | DMPK2 | 57.3% | 42.7% |
| 6 | AURORA_A | 55.6% | 44.4% |
| 7 | AURORA_C | 54.5% | 45.5% |
| 8 | JAK3 | 51.1% | 48.9% |
| 9 | MYLK4 | 50.0% | 50.0% |
| 10 | SRPK1 | 47.9% | 52.1% |
| 11 | STK38_NDR1 | 47.7% | 52.3% |
| 12 | PKA | 37.8% | 62.2% |
| 13 | BMPR2 | 35.8% | 64.2% |
| 14 | PKACB | 34.8% | 65.2% |
| 15 | TAK1 | 34.7% | 65.3% |
| 16 | FLT3 | 33.2% | 66.8% |
| 17 | MARK4 | 32.8% | 67.2% |
| 18 | CLK1 | 32.1% | 67.9% |
| 19 | MEK1 | 31.8% | 68.2% |
| 20 | RET | 31.3% | 68.7% |
Selectivity landscape
Where Abrocitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Abrocitinib.
Atlas insights for Abrocitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target9%
Off-target91%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1209.62 | |
| ALLOGRAFT_REJECTION | 3276.24 | |
| ANDROGEN_RESPONSE | 681.65 | |
| ANGIOGENESIS | 425.33 | |
| APICAL_JUNCTION | 2840.33 | |
| APICAL_SURFACE | 481.92 | |
| APOPTOSIS | 2947.72 | |
| BILE_ACID_METABOLISM | 281.99 | |
| CHOLESTEROL_HOMEOSTASIS | 309.22 | |
| COAGULATION | 285.48 | |
| COMPLEMENT | 1583.32 | |
| DNA_REPAIR | 761.87 | |
| E2F_TARGETS | 2382.37 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 753.99 | |
| ESTROGEN_RESPONSE_EARLY | 1529.42 | |
| ESTROGEN_RESPONSE_LATE | 1422.49 | |
| FATTY_ACID_METABOLISM | 278.90 | |
| G2M_CHECKPOINT | 2396.32 | |
| GLYCOLYSIS | 910.18 | |
| HEDGEHOG_SIGNALING | 301.36 | |
| HEME_METABOLISM | 938.36 | |
| HYPOXIA | 1701.14 | |
| IL2_STAT5_SIGNALING | 1562.80 | |
| IL6_JAK_STAT3_SIGNALING | 3210.29 | |
| INFLAMMATORY_RESPONSE | 2414.81 | |
| INTERFERON_ALPHA_RESPONSE | 589.89 | |
| INTERFERON_GAMMA_RESPONSE | 3439.75 | |
| KRAS_SIGNALING_DN | 293.18 | |
| KRAS_SIGNALING_UP | 1063.86 | |
| MITOTIC_SPINDLE | 2071.94 | |
| MTORC1_SIGNALING | 1289.37 | |
| MYC_TARGETS_V1 | 1518.97 | |
| MYC_TARGETS_V2 | 393.22 | |
| MYOGENESIS | 1488.50 | |
| NOTCH_SIGNALING | 125.70 | |
| OXIDATIVE_PHOSPHORYLATION | 483.20 | |
| P53_PATHWAY | 1589.84 | |
| PANCREAS_BETA_CELLS | 103.00 | |
| PEROXISOME | 314.74 | |
| PI3K_AKT_MTOR_SIGNALING | 3671.69 | |
| PROTEIN_SECRETION | 854.43 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 154.73 | |
| SPERMATOGENESIS | 765.67 | |
| TGF_BETA_SIGNALING | 794.67 | |
| TNFA_SIGNALING_VIA_NFKB | 2278.00 | |
| UNFOLDED_PROTEIN_RESPONSE | 777.14 | |
| UV_RESPONSE_DN | 1988.42 | |
| UV_RESPONSE_UP | 1445.94 | |
| WNT_BETA_CATENIN_SIGNALING | 928.85 | |
| XENOBIOTIC_METABOLISM | 459.23 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.857 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.845 |
| TCGA-CV-7424-01A-11R-2081-07 | — | 0.840 |
| SRR10899984 | — | 0.835 |
| SRR12202498 | — | 0.834 |
Annotations
Sign in to read and post annotations.
Loading…